Gland Pharma Limited
NSE: GLAND.NS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- National Stock Exchange of India
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Shyamakant Giri
- Employees
- 4,217
- Headquarters
- Hyderabad, India
- IPO year
- 2020
- Market cap
- ₹313.8B
- Website
- https://www.glandpharma.com
Loading GLAND…
Loading profile data…Frequently asked questions about GLAND
What does Gland Pharma Limited (GLAND.NS) do?
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as ant...
Where does GLAND.NS trade?
Gland Pharma Limited (GLAND.NS) trades on the National Stock Exchange of India.
What sector is GLAND.NS in?
Gland Pharma Limited (GLAND.NS) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Gland Pharma Limited?
Shyamakant Giri is the chief executive officer of Gland Pharma Limited (GLAND.NS).
Where is Gland Pharma Limited headquartered?
Gland Pharma Limited is headquartered in India.
Does GLAND.NS pay a dividend?
Yes — Gland Pharma Limited (GLAND.NS) paid a trailing twelve-month dividend of INR 18.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did GLAND.NS go public?
Gland Pharma Limited (GLAND.NS) completed its initial public offering in 2020.